VIA
BCAX

Virtus Investment Advisers’s Bicara Therapeutics BCAX Stock Holding History

Virtus Investment Advisers’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$293K Buy
14,755
+360
+3% +$6.2K 0.08% 282
2025
Q4 		$242K Buy
14,395
+4,560
+46% +$77.9K 0.07% 343
2025
Q3 		$155K Buy
9,835
+1,708
+21% +$19.1K 0.04% 370
2025
Q2 		$75.5K Sell
8,127
-970
-11% -$11.6K 0.03% 432
2025
Q1 		$119K Buy
+9,097
New +$121K 0.03% 395

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Virtus Investment Advisers's BCAX Position: Q1 2026 in Review

Virtus Investment Advisers increased its Bicara Therapeutics (BCAX) stake by 2.5% in Q1 2026, buying an estimated $6.2K and bringing the position to 14,755 shares worth $293K. The position accounts for 0.08% of the portfolio, ranked #282.

Virtus Investment Advisers first reported a position in BCAX in Q1 2025 and has held it in 5 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Virtus Investment Advisers held 14,755 shares of Bicara Therapeutics worth $293K as of Q1 2026.
  • Virtus Investment Advisers bought 360 Bicara Therapeutics shares in Q1 2026, an estimated $6.2K.
  • Bicara Therapeutics made up 0.08% of Virtus Investment Advisers's portfolio in Q1 2026, its #282 holding.
  • Virtus Investment Advisers first reported a position in Bicara Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.